Potentiation of the Growth-Inhibitory Effects of Vitamin D in Prostate Cancer by Genistein

Nutrition Reviews

Volumn 65, Issue SUPPL.2, 2007, Pages

  Krishnan, Aruna V ^a   Swami, Srilatha ^a   Moreno, Jacqueline ^a   Bhattacharyya, Rumi B ^a   Peehl, Donna M ^a   Feldman, David ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CALCITRIOL; GENISTEIN; VITAMIN D;

CELL CULTURE; CYTOLOGY; DRUG EFFECT; DRUG POTENTIATION; HUMAN; MALE; PROSTATE; PROSTATE TUMOR; REVIEW;

ANTINEOPLASTIC AGENTS; CALCITRIOL; DRUG SYNERGISM; GENISTEIN; HUMANS; MALE; PROSTATE; PROSTATIC NEOPLASMS; TUMOR CELLS, CULTURED; VITAMIN D;

EID: 35148849637     PISSN: 00296643     EISSN: 17534887     Source Type: Journal    
DOI: 10.1111/j.1753-4887.2007.tb00338.x     Document Type: Article

References (22)

1. Beer TM, Myrthue A. Calcitriol in cancer treatment: from the lab to the clinic. Mol Cancer Ther 2004;3:S373-S381.
2. Krishnan AV, Peehl DM, Feldman D. Inhibition of prostate cancer growth by vitamin D: regulation of target gene expression. J Cell Biochem 2003;88:S363-S371.
3. Mentor-Marcel R., Lamartiniere CA, Eltoum IA, Greenberg NM, Elgavish A. Dietary genistein improves survival and reduces expression of os-teopontin in the prostate of transgenic mice with prostatic adenocarcinoma (TRAMP). J Nutr 2005;135:S989-S995.
4. Sarkar FH, Li Y. The role of isoflavones in cancer chemoprevention. Front Biosci 2004;9:S2714-S2724.
5. Trump DL, Hershberger PA, Bernardi RJ, et al. Anti-tumor activity of calcitriol: pre-clinical and clinical studies. J Steroid Biochem Mol Biol 2004;89-90:S519-S526.
6. Moreno J., Krishnan AV, Swami S., Nonn L., Peehl DM, Feldman D. Regulation of prostaglandin metabolism by calcitriol attenuates growth stimulation in prostate cancer cells. Cancer Res 2005;65:S7917-S7925.
7. Barnes S., Peterson TG, Coward L. Rationale for the use of genistein-containing soy matrices in chemoprevention trials for breast and prostate cancer. J Cell Biochem Suppl 1995;22:S181-S187.
8. Messina MJ, Persky V., Setchell KD, Barnes S. Soy intake and cancer risk: a review of the in vitro and in vivo data. Nutr Cancer 1994;21:S113-S131.
9. Rao A., Coan A., Welsh JE, Barclay WW, Koumenis C., Cramer SD. Vitamin D receptor and p21/WAF1 are targets of genistein and 1, 25-dihydroxyvitamin D3 in human prostate cancer cells. Cancer Res 2004;64:S2143-S2147.
10. Xiang H., Schevzov G., Gunning P., Williams HM, Silink M. A comparative study of growth-inhibitory effects of isoflavones and their metabolites on human breast and prostate cancer cell lines. Nutr Cancer 2002;42:S224-S232.
11. Wang J., Eltoum IE, Lamartiniere CA. Genistein che-moprevention of prostate cancer in TRAMP mice. J Carcinogenesis 2007;6:S3.
12. Beer TM, Lemmon D., Lowe BA, Henner WD. High-dose weekly oral calcitriol in patients with a rising PSA after prostatectomy or radiation for prostate carcinoma. Cancer 2003;97:S1217-S1224.
13. Gross C., Stamey T., Hancock S., Feldman D. Treatment of early recurrent prostate cancer with 1, 25-dihydroxyvitamin D3 (calcitriol). J Urol 1998;159:S2035-S2039.
14. Beer TM, Ryan CW, Venner PM, et al. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus do-cetaxel in androgen-independent prostate cancer: a report from the ASCENT investigators. J Clin Oncol 2007;25:S669-S674.
15. Miller GJ, Stapleton GE, Hedlund TE, Moffat KA. Vitamin D receptor expression, 24-hydroxylase activity, and inhibition of growth by 1alpha, 25-dihy-droxyvitamin D3 in seven human prostatic carcinoma cell lines. Clin Cancer Res 1995;1:S997-S1003.
16. Skowronski RJ, Peehl DM, Feldman D. Vitamin D and prostate cancer: 1, 25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology 1993;132:S1952-S1960.
17. Ly LH, Zhao XY, Holloway L., Feldman D. Liarozole acts synergistically with 1alpha, 25-dihydroxyvita-min D3 to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity. Endocrinology 1999;140:S2071-S2076.
18. Peehl DM, Seto E., Hsu JY, Feldman D. Preclinical activity of ketoconazole in combination with calcitriol or the vitamin D analogue EB 1089 in prostate cancer cells. J Urol 2002;168:S1583-S1588.
19. Farhan H., Wahala K., Cross HS. Genistein inhibits vitamin D hydroxylases CYP24 and CYP27B1 expression in prostate cells. J Steroid Biochem Mol Biol 2003;84:S423-S429.
20. Wietzke JA, Welsh J. Phytoestrogen regulation of a Vitamin D3 receptor promoter and 1, 25-dihydroxyvitamin D3 actions in human breast cancer cells. J Steroid Biochem Mol Biol 2003;84:S149-S157.
21. Swami S., Krishnan AV, Peehl DM, Feldman D. Genistein potentiates the growth inhibitory effects of 1, 25-dihydroxyvitamin D(3) in DU145 human prostate cancer cells: role of the direct inhibition of CYP24 enzyme activity. Mol Cell Endocrinol 2005;12:S12.
22. Rao A., Woodruff RD, Wade WN, Kute TE, Cramer SD. Genistein and vitamin D synergistically inhibit human prostatic epithelial cell growth. J Nutr 2002;132:S3191-S3194.